Scancell (LON:SCLP) Releases Quarterly Earnings Results

Scancell (LON:SCLP) posted its earnings results on Friday. The company reported GBX (1.73) EPS for the quarter, Digital Look Earnings reports. Scancell had a negative net margin of 116.98% and a positive return on equity of 90.29%.

Scancell Stock Performance

Shares of SCLP stock opened at GBX 9.36 on Friday. The company has a market capitalization of £127.01 million, a P/E ratio of -17.02 and a beta of 0.69. The business’s 50 day moving average is GBX 9.68 and its two-hundred day moving average is GBX 13.98. The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29. Scancell has a 12-month low of GBX 9.10 and a 12-month high of GBX 29.50.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.